Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald F Watts

Showing results (631-640 of 706) with videos related to

Pageof 71
Sort By:
Plos Biology|December 9, 2020
Correction: High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studiesHabtamu B Beyene, Gavriel Olshansky, Adam Alexander T Smith, et al.
Plos Biology|September 28, 2020
High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studiesHabtamu B Beyene, Gavriel Olshansky, Adam Alexander T Smith, et al.
The Lancet. Diabetes & Endocrinology|December 21, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trialFrederick J Raal, Jean Bergeron, Daniel Gaudet, et al.
JAMA|April 3, 2022
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) LevelsSteven E Nissen, Kathy Wolski, Craig Balog, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|October 31, 2013
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary], Scott M Grundy, Hidenori Arai, et al.
Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 4, 2024
Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitionersShirin Ibrahim, Jim N de Goeij, Nick S Nurmohamed, et al.
BMJ Open|October 28, 2017
An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study"Jing Pang, Miao Hu, Jie Lin, et al.
Heart, Lung & Circulation|October 21, 2023
Barriers to and Facilitators of Implementing Guidelines for Detecting Familial Hypercholesterolaemia in AustraliaMitchell N Sarkies, Luke Testa, Stephanie Best, et al.
NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.
Pageof 71

Showing results (631-640 of 706) with videos related to

Sort By:
Pageof 71
Plos Biology|December 9, 2020
Correction: High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studiesHabtamu B Beyene, Gavriel Olshansky, Adam Alexander T Smith, et al.
Plos Biology|September 28, 2020
High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studiesHabtamu B Beyene, Gavriel Olshansky, Adam Alexander T Smith, et al.
The Lancet. Diabetes & Endocrinology|December 21, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trialFrederick J Raal, Jean Bergeron, Daniel Gaudet, et al.
JAMA|April 3, 2022
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) LevelsSteven E Nissen, Kathy Wolski, Craig Balog, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|October 31, 2013
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary], Scott M Grundy, Hidenori Arai, et al.
Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 4, 2024
Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitionersShirin Ibrahim, Jim N de Goeij, Nick S Nurmohamed, et al.
BMJ Open|October 28, 2017
An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study"Jing Pang, Miao Hu, Jie Lin, et al.
Heart, Lung & Circulation|October 21, 2023
Barriers to and Facilitators of Implementing Guidelines for Detecting Familial Hypercholesterolaemia in AustraliaMitchell N Sarkies, Luke Testa, Stephanie Best, et al.
NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.
Pageof 71